1. Home
  2. MIRM vs TECH Comparison

MIRM vs TECH Comparison

Compare MIRM & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • TECH
  • Stock Information
  • Founded
  • MIRM 2018
  • TECH 1976
  • Country
  • MIRM United States
  • TECH United States
  • Employees
  • MIRM N/A
  • TECH N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • TECH Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • MIRM Health Care
  • TECH Health Care
  • Exchange
  • MIRM Nasdaq
  • TECH Nasdaq
  • Market Cap
  • MIRM 1.9B
  • TECH 8.0B
  • IPO Year
  • MIRM 2019
  • TECH 1989
  • Fundamental
  • Price
  • MIRM $40.80
  • TECH $50.24
  • Analyst Decision
  • MIRM Strong Buy
  • TECH Buy
  • Analyst Count
  • MIRM 11
  • TECH 8
  • Target Price
  • MIRM $58.55
  • TECH $81.14
  • AVG Volume (30 Days)
  • MIRM 438.4K
  • TECH 2.3M
  • Earning Date
  • MIRM 05-07-2025
  • TECH 05-07-2025
  • Dividend Yield
  • MIRM N/A
  • TECH 0.64%
  • EPS Growth
  • MIRM N/A
  • TECH N/A
  • EPS
  • MIRM N/A
  • TECH 0.98
  • Revenue
  • MIRM $336,888,000.00
  • TECH $1,196,016,000.00
  • Revenue This Year
  • MIRM $29.51
  • TECH $8.19
  • Revenue Next Year
  • MIRM $20.27
  • TECH $8.85
  • P/E Ratio
  • MIRM N/A
  • TECH $51.28
  • Revenue Growth
  • MIRM 80.76
  • TECH 4.46
  • 52 Week Low
  • MIRM $23.83
  • TECH $46.44
  • 52 Week High
  • MIRM $54.23
  • TECH $85.57
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 45.27
  • TECH 40.99
  • Support Level
  • MIRM $38.22
  • TECH $46.01
  • Resistance Level
  • MIRM $39.87
  • TECH $53.54
  • Average True Range (ATR)
  • MIRM 2.27
  • TECH 3.20
  • MACD
  • MIRM 0.23
  • TECH 0.29
  • Stochastic Oscillator
  • MIRM 61.83
  • TECH 50.84

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About TECH Bio-Techne Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Share on Social Networks: